Annual General Meeting

Empros will hold its annual general meeting on the 5th of May. Documents requested by shareholders no later than 26th of April 2022, will be published here no later than 1 May 2022.…

RECRUITMENT COMPLETE; EMPROS SECOND CLINICAL TRIAL

On May 25th Empros Pharma started our second clinical trial – a Phase IIa proof-of-concept trial. It is a golden standard randomized, placebo controlled double blinded clinical trial where we compare two different doses of EMP16-02 and placebo. The primary …

Empros first clinical trial published

Empros first clinical trial, closed in 2017 was recently published in Obesity Science and Practice, see full text article here. In this phase 2a trial Empros compared three different doses of EMP16 with Xenical. The trial demonstrated that EMP16 …

Empros Pharma strengthen the Board of Directors

At an extraordinary general meeting held in Q1 2020, Empro’s owners decided to appoint Eugen Steiner, Milan Zdravkovic and Anne Bloch Thomsen as new Directors of the Board. The three new members add competence in entrepreneurship, venture capital logics, Obesity, …

Empros Pharma participates in Bio Korea

CEO Arvid Söderhäll participated in the Bio-Korea conference in Seoul in May. South Korea represents a vibrant region with an impressive traction. Empros Pharma has established contacts with investors, pharmaceutical industry, key opinion leaders, regulatory authority as well as consultants.…

Pressrelease Phase 2a trial

Swedish Start-Up Pharma reveals positive Phase 2a trial – results from a novel oral medication treatment of obesity

The Swedish Pharmaceutical start-up Empros Pharma AB has new clinical results from a Phase 2a trial of its first novel and unique

Phase 2a trial concluded

The prevalence of overweight and obesity is increasing worldwide. In 2015, it was estimated that about 108 million children and 604 million adults were obese worldwide. The overall prevalence of obesity was 5.0% among children and 12.0% among adults. Among …